Christina Rapp Prescott, MD, PhD discusses the similarities between cataract surgery and refractive surgery and how careful management of patient expectations is key to achieving optimal outcomes.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Alcon’s Clareon Panoptix Pro IOL has been approved for patients with cataracts in Canada.

As Ophthalmology Times celebrates its 50th anniversary, ophthalmologists share their insights on the profession’s evolution, celebrating technological advances and paradigm shifts that continue to define modern eye care.

The US Food and Drug Administration (FDA) recently agreed to the expansion of Atsena Therapeutics’ ongoing phase 1/2 LIGHTHOUSE study of ATSN-201 into a continuous phase 1/2/3 trial.

Alcon’s Clareon Panoptix Pro IOL has been approved for patients with cataracts in Canada. The IOL utilizes the company’s ENLIGHTEN NXT Optical technology, which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.

Christina Rapp Prescott, MD, PhD discusses the similarities between cataract surgery and refractive surgery and how careful management of patient expectations is key to achieving optimal outcomes.

A new study found that the use of cannabis might exert a moderately protective effect against the development of proliferative vitreoretinopathy (PVR) after repair of retinal detachments (RDs).

As Ophthalmology Times celebrates its 50th anniversary, ophthalmologists shared their insights on the profession’s evolution, celebrating technological advances and paradigm shifts that continue to define modern eye care.

Belite Bio, Inc. has completed enrollment in the PHOENIX trial. The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal Phase 3 trial for this oral medication.

PulseSight Technologies recently announced the successful dosing of the first patient in the phase I clinical trial PST-611-CT1, investigating the safety and tolerability of PST-611 for the treatment of AMD and geographic atrophy (GA).

A class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, has been issued in the United Kingdom after Laboratoires Théa notified the MHRA of an event during manufacturing that may increase the risk of microbial contamination in the product.

First-time results of the phase 2 VERONA (NCT06099184) trial of the vorolanib intravitreal insert known as EYP-1901 (Duravyu; EyePoint) for diabetic macular edema (DME) were presented at the Retina World Congress 2025 in Fort Lauderdale, Florida.

Beacon Therapeutics has completed enrollment in its registrational phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP).

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study (NCT06962839). THULITE will evaluate the efficacy, safety, and tolerability of BI 1815368, an oral medication for the treatment of diabetic macular edema (DME).

LENZ Therapeutics and Laboratoires Théa have announced a license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada.

4D Molecular Therapeutics has announced it is accelerating its 4D-150 4FRONT phase 3 program in wet age-related macular degeneration (wet AMD) and will lay off approximately 25% of staff.

Two phase 2a clinical trials showed positive results for the PER-001 intravitreal implant as the first disease-modifying treatment for glaucoma and diabetic retinopathy (DR), according to a press release issued by Perfuse Therapeutics.

Alcon is continuing its trend of acquisitions in 2025 with the recent announcement that the company will acquire LumiThera, Inc. and its photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD).

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.